GNBT.OB

[Terliso]

Update:
We just got stopped at $2.18

Applause Rams that's a nice 20% profits

[jax420]

Would anyone care to voice their opinion as to what direction they feel the stock will head after todays pullback.

[thai626]

The gap filled and I am back in at 2.23

Same here Tokyo.........I got filled at 2.22.  Just testing the water here.......hopefully, it's holy water.  Let's see what tomorrow brings!     I put in a stop just in case at 2.10 to limit any potential loss. 

[Ramsburg]

Update:
We got stopped from our position today closing down a 20% fast profit here... Good, but the exit plan was not the best since we gave away half of this move. Anyway I wasn't sincerely expecting such a hard correction today.

We still enjoy GNBT a lot, and we are going to continue watching this stock for short term, since current price volatility is probably just «chart noise».

I'm not sure what could be the price development for the next few days, but I know for sure that I would buy GNBT again if we see another red candle like this... so while thinking what is the current short term technical pattern, we'll just post a limit entry order significantly below current price near the breakout area.

This plan will most probably be updated soon.

Trading Plan:
Buy GNBT below $2.00

[tokyopua]

The gap filled and I am back in at 2.23

Same here Tokyo.........I got filled at 2.22.  Just testing the water here.......hopefully, it's holy water.  Let's see what tomorrow brings!     I put in a stop just in case at 2.10 to limit any potential loss. 

Hey Thai, actually I wound up getting out at 2.19 right near the close, was thinking that I didnt like the market in general and sold 40% of my positions.  Actually I held BCRX and NVAX because I think bird flu stocks will be in bull mode regardless, but figured since I didnt get the expected gap bounce that I was expecting in GNBT, I had better just trust the tape since its always right and GNBT was being treated as too overextended. 

The way 2.26 held so many times this morning was what I expected to see happen at 2.25 which would have closed the gap.  I should have known something was fishy when it was happening at 2.26.

So, for now I am just going to go along with 3SOF guidance to buy back around 2.00 if it happens.    What I learned last season from trading bird flu stocks is that you get many chances to make money in them 

[setravis]

JMHO of course.....higher ground.
Go to prior page.

52wk Range: 0.69 - 5.02
Volume: 3,220,744
Avg Vol (3m): 2,309,350

Technicals
Most Actives
Percentage Gainer

Last Price Quote is:
24.64%above 13-day MA
42.29%above 50-day MA
RS Rating: 96 

Fundamentals
Key Data:
Market Cap (M): $147.74 
P/E Ratio: NA 
PEG Ratio: N/A 
Next Earnings: N/A
Last Analyst Rating: Buy

Double Bottom (Reversal) Pattern
The double bottom is a major reversal pattern that forms after an extended downtrend. As its name implies, the pattern is made up of two consecutive troughs that are roughly equal, with a moderate peak in between.

Although there can be variations, the classic double bottom usually marks an intermediate or long-term change in trend. Many potential double bottoms can form along the way down, but until key resistance is broken, a reversal cannot be confirmed.

It is important to remember that the double bottom is an intermediate to long-term reversal pattern that will not form in a few days. Even though formation in a few weeks is possible, it is preferable to have at least 4 weeks between lows. Bottoms usually take longer than tops to form and patience can often be a virtue. Give the pattern time to develop and look for the proper clues. The advance off of the first trough should be 10-20%. The second trough should form a low within 3% of the previous low and volume on the ensuing advance should increase. Volume indicators such as Chaikin Money Flow, OBV and Accumulation/Distribution can be used to look for signs of buying pressure. Just as with the double top, it is paramount to wait for the resistance breakout. The formation is not complete until the previous reaction high is taken out.

[setravis]

Rams,
Meus comentários, dois centavos valor, localizado aqui.

http://www.3stocksonfire.org/trading/index.php?topic=5051.225

Tenha um dia agradável. Desfrute seu fim de semana ! 
Cumprimentos.......

[Ramsburg]

Rams,
Meus comentários, dois centavos valor, localizado aqui.

http://www.3stocksonfire.org/trading/index.php?topic=5051.225

Tenha um dia agradável. Desfrute seu fim de semana ! 
Cumprimentos.......

Obrigado Setravis É bom ler português de vez em quando

hehehe but «Two Cents» («dois centavos») in Portuguese actually means only 2 cents on a monetary way, so I guess I have to give you 2 applauds instead because I dont got any change here 

Thanks Setravis, you been doing a great job on the free boards ! 

[Ramsburg]

Update:
GNBT has been holding quite well the recent high levels, this looks like a consolidation, volume has also dropped, but this is normal on consolidation areas.
But to be honest I don't feel like buying GNBT at these levels yet, because there are still a lot of short term players inside, probably weak hands that can be easily shaken.
This can turnout to be a mistake, because I'm looking to see GNBT above $3 mid term, but we'll keep the same plan for now and wait.

Trading Plan:
Buy GNBT near $2.00

Regards

[Ramsburg]

Update:
GNBT had a bad reaction to its 10Q released after the market:
- GENEREX BIOTECHNOLOGY CORP Files SEC form 10-K, Annual Report
The stock dropped in after hours trading reaching a low of $2.00 and closing extended trading @ $2.10 (intraday chart with extended hours in attach). The stock will probably open tomorrow's session with a gap down to this price levels.

We don't want to play this earnings reaction volatility so we are just going to quit this re-entry plan for now and watch from the side lines.

Trading Plan:
No plan in place.

Regards,

[tokyopua]

Back in GNBT here at 1.90, expecting the 200sma to act as closing support (1.8985).

[soxguy]

good call on gnbt toky.  i also jumped in at 1.90 yesterday...as always,we'll see

[setravis]

Press Release Source: Generex Biotechnology


Generex Biotechnology CEO to Present at The C.E. Unterberg, Towbin Life Sciences Conference
Wednesday October 25, 7:00 am ET


TORONTO--(MARKET WIRE)--Oct 25, 2006 -- Generex Biotechnology Corporation (NASDAQ:GNBT - News), the leader in drug delivery for metabolic diseases through the inner lining of the mouth, announced today that Anna Gluskin, the Company's President & Chief Executive Officer, will be presenting at The C.E. Unterberg, Towbin Life Sciences Conference in New York City, October 30 - 31, 2006. Ms. Gluskin's presentation is scheduled for 1 p.m. (EST) on Monday, October 30, 2006 at The Palace Hotel.


"I am looking forward to providing the investment community with an update on the status of our product pipeline, including Generex Oral-lyn(TM), Glucose RapidSpray(TM), metformin gum, and the Antigen Express immunotherapeutic vaccine programs for breast and prostate cancer and avian influenza," Ms. Gluskin said.

About Generex

Generex is engaged in the research and development of drug delivery systems and technologies. Generex has developed a proprietary platform technology for the delivery of drugs into the human body through the oral cavity (with no deposit in the lungs). The Company's proprietary liquid formulations allow drugs typically administered by injection to be absorbed into the body by the lining of the inner mouth using the Company's proprietary RapidMist(TM) device. The Company's flagship product, oral insulin (Generex Oral-lyn(TM)), which is available for sale in Ecuador for the treatment of patients with Type-1 and Type-2 diabetes, is in various stages of clinical trials around the world. For more information, visit the Generex website at www.generex.com.

Safe Harbor Statement: This release and oral statements made from time to time by Generex representatives concerning the same subject matter may contain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. These statements can be identified by introductory words such as "expects," "plans," "intends," "believes," "will," "estimates," "forecasts," "projects" or words of similar meaning, and by the fact that they do not relate strictly to historical or current facts. Forward-looking statements frequently are used in discussing potential product applications, potential collaborations, product development activities, clinical studies, regulatory submissions and approvals, and similar operating matters. Many factors may cause actual results to differ from forward-looking statements, including inaccurate assumptions and a broad variety of risks and uncertainties, some of which are known and others of which are not. Known risks and uncertainties include those identified from time to time in the reports filed by Generex with the Securities and Exchange Commission, which should be considered together with any forward-looking statement. No forward-looking statement is a guarantee of future results or events, and one should avoid placing undue reliance on such statements. Generex cannot be sure when or if it will be permitted by regulatory agencies to undertake additional clinical trials or to commence any particular phase of clinical trials. Because of this, statements regarding the expected timing of clinical trials cannot be regarded as actual predictions of when Generex will obtain regulatory approval for any "phase" of clinical trials. Generex claims the protection of the safe harbor for forward-looking statements that is contained in the Private Securities Litigation Reform Act.


Contact:
     Contacts:
     Shayne Gilliatt
     Generex Biotechnology Corporation
     Phone: (800) 391-6755
     or (416) 364-2551
     
     Andrew Hellman
     CEOcast, Inc.
     Phone: (212) 732-4300
     
     Dolores Naney
     Rubenstein Public Relations
     Phone: (212) 843-8018
--------------------------------------------------------------------------------
Source: Generex Biotechnology

[setravis]

A speculative hope.......... Some more good news would be nice also.
JMHO, should start going back up from here. Let's see if I'm right ?
It's just about @ it's price before the spike.Retest of the 200-day MA, OverSold.....
The gap down ,makes it cheap !

Support @ $1.68...1.54...1.40...1.28
Resistance @ $1.98...2.30...2.44...2.93

52wk Range: 0.80 - 5.02
Volume: 2,325,477
Avg Vol (3m): 2,659,590

Technicals
MACD is Bullish
Stochastic is Bullish
Most Actives

Last Price Quote is:
-3.53%below 13-day MA
8.52%above 50-day MA
RS Rating: 96 

Fundamentals
Key Data:
Market Cap (M): $147.74 
P/E Ratio: NA 
PEG Ratio: N/A 
Next Earnings: N/A
Last Analyst Rating: Buy

[tokyopua]

good call on gnbt toky.  i also jumped in at 1.90 yesterday...as always,we'll see

Up about 6% from our buy point, good start so far Soxguy!    Lets hope it goes higher. 

I am a bit surprised there isnt more bird flu news yet like there was at this time last year, but GNBT has its other diabetes products kicking until then.  As I have said before, based on charts from last year, the stock has the potential to easily double from here within half a year if not sooner.

I will probalby keep getting in and out if it overheats too much like it did recently of course, but so far 2 our of 3 rides I have taken on GNBT recently were very profitable, and the one loss was very small